|1.||Fujii, Yoshitaka: 17 articles (12/2011 - 05/2002)|
|2.||Friedman, Benjamin W: 7 articles (01/2016 - 10/2008)|
|3.||Gallagher, E John: 7 articles (01/2016 - 10/2008)|
|4.||Solorzano, Clemencia: 6 articles (01/2016 - 10/2008)|
|5.||Esses, David: 6 articles (01/2016 - 10/2008)|
|6.||Fujii, Y: 6 articles (10/2004 - 01/2000)|
|7.||Parkman, Henry P: 5 articles (07/2015 - 08/2010)|
|8.||Tanaka, H: 5 articles (03/2001 - 01/2000)|
|9.||Baracat, Edmund Chada: 4 articles (12/2015 - 09/2006)|
|10.||Rudd, John A: 4 articles (11/2014 - 12/2003)|
04/01/2015 - "Recent studies show that, especially in the therapy of opioid-triggered vomiting, metoclopramide is not significantly effective when compared to placebo. "
11/01/1989 - "There was a significant reduction in the number of episodes of vomiting during the first 24 h in patients receiving the metoclopramide combination (P = 0.0001). "
11/01/1984 - "Pharmacokinetics and efficacy of high-dose metoclopramide given by continuous infusion for the control of cytotoxic drug-induced vomiting."
01/01/1985 - "The antiemetic potency of metoclopramide increased in a log linear manner, giving from 40% to 95% protection against emesis. "
08/01/2011 - "All three studies were included in the final meta-analysis that demonstrated an overall result of no difference between metoclopramide and placebo for the primary outcome of vomiting (odds ratios 0.72; 95% confidence intervals 0.11-4.58). "
06/01/2000 - "There was a trend for improvement in the intensity of all symptoms on controlled-release metoclopramide with the exception of appetite, but this trend only reached statistical significance for nausea. "
12/01/1968 - "Metoclopramide in the treatment of nausea: a double blind trial."
03/01/2015 - "Six patients complained of nausea that eased with the administration of ev metoclopramide. "
04/05/2014 - "The target of this paper is aimed to discuss the fast and newly techniques in order to assessment the metoclopramide (Mcp) nausea drug in pure form in solid and solution shape with different kind of π-acceptors upon charge transfer interactions. "
04/05/2014 - "Charge-transfer interactions of metoclopramide nausea drug against six kind of π-acceptors: spectral and thermal discussions."
|3.||Postoperative Nausea and Vomiting (PONV)
03/01/2012 - "In conclusion, this review suggests that metoclopramide is effective and safe for IONV and PONV prophylaxis in this patient population. "
03/01/2012 - "This meta-analysis assesses the efficacy of metoclopramide for prophylaxis against intra- and postoperative nausea and vomiting (IONV and PONV) in parturients undergoing CD under neuraxial anaesthesia. "
11/01/2012 - "A post hoc analysis examining three studies with questioned validity performed by the author Yoshitaka Fujii that would meet criteria for inclusion in the current study did not demonstrate a significant benefit of metoclopramide compared with control on the incidence of 24 h PONV. "
11/01/2012 - "Thirty trials evaluating the effect of 10 mg systemic metoclopramide in 3328 subjects on PONV outcomes were included. "
11/01/2012 - "A wide search was performed to identify randomized clinical trials that evaluated systemic 10 mg metoclopramide as a prophylactic agent to reduce PONV. "
|4.||Migraine Disorders (Migraine)
01/01/2008 - "Metoclopramide appears to be an effective initial medical treatment for migraine headaches in the emergency department setting, but its pharmacologic mechanism remains incompletely understood. "
12/11/2004 - "Metoclopramide is an effective treatment for migraine headache and may be effective when combined with other treatments. "
10/01/1990 - "IV metoclopramide as a single agent is effective and safe therapy for migraine in the ED."
02/01/1993 - "The efficacy of metoclopramide in the treatment of migraine headache."
03/01/2015 - "Although the studies comparing parenteral metoclopramide to placebo in ceasing migraine headache favor metoclopramide to placebo and lower rates of rescue drug need, however, they lack high methodological quality even to perform a meta-analysis. "
01/01/1992 - "In the present tumor study, the dose scheduling of metoclopramide in combination with radiation was evaluated, and metoclopramide was shown to be most effective in potentiating the cytotoxic effect of radiation when administered one hour before radiation. "
05/01/1997 - "Patient gender and age, clinical symptoms and signs, tumor localization, detection methods, findings on imaging studies, urinary catecholamine concentrations, results of metoclopramide stimulation tests, treatments at operation and tumor size were evaluated. "
04/01/2002 - "Anderson Cancer Center between 1994 and 1996, who were treated with a clinical care pathway that included NGT removal on postoperative day 1 and immediate use of promotility agents such as metoclopramide. "
01/01/2002 - "Forty-eight patients (25 female and 23 male; mean age 63 +/- 11 years) with a minimum two-week history of cancer-associated gastrointestinal symptoms were assigned to a single, open-label treatment group and received controlled-release metoclopramide 20 mg-80 mg q12h for a maximum period of 12 weeks (mean 46 +/- 35 days). "
06/01/2000 - "These results indicate that controlled-release metoclopramide reduces gastrointestinal symptoms in this population of advanced cancer patients."
|1.||Drug Therapy (Chemotherapy)
|5.||Gynecologic Surgical Procedures (Gynecologic Surgery)